Pharvaris (PHVS) to Release Quarterly Earnings on Wednesday

Pharvaris (NASDAQ:PHVS) is expected to be posting its Q1 2025 quarterly earnings results before the market opens on Wednesday, August 13th. Analysts expect Pharvaris to post earnings of ($0.87) per share for the quarter.

Pharvaris (NASDAQ:PHVS) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.89) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.09). On average, analysts expect Pharvaris to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Pharvaris Trading Up 3.6%

Shares of NASDAQ:PHVS opened at $20.84 on Tuesday. The stock has a market capitalization of $1.09 billion, a PE ratio of -6.92 and a beta of -2.81. Pharvaris has a 1 year low of $11.51 and a 1 year high of $26.33. The firm has a fifty day moving average price of $19.29 and a 200 day moving average price of $17.12.

Institutional Investors Weigh In On Pharvaris

An institutional investor recently raised its position in Pharvaris stock. Geode Capital Management LLC increased its position in shares of Pharvaris N.V. (NASDAQ:PHVS) by 41.1% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 54,102 shares of the company’s stock after buying an additional 15,769 shares during the quarter. Geode Capital Management LLC owned 0.10% of Pharvaris worth $952,000 at the end of the most recent quarter.

Analysts Set New Price Targets

Several research firms recently weighed in on PHVS. Wedbush reissued an “outperform” rating and set a $27.00 price objective on shares of Pharvaris in a research report on Thursday, June 5th. Guggenheim started coverage on Pharvaris in a report on Wednesday, June 11th. They set a “buy” rating and a $32.00 price target for the company. Finally, Cantor Fitzgerald lowered their price objective on shares of Pharvaris from $28.00 to $25.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 14th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $36.20.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.